Original Article
The expression of EGFL7 and E-Cadherin in human adenocarcinoma of esophagogastric junction and their clinical significance

Yun-Liang Wang1*, Song-Tao Xu2*, Xiao-Chun Shen3*, Zhi Li4, Xin Zhao1, Jin Zhou1

1Department of General Surgery, The First Affiliated Hospital of Soochow University, No. 188, Shizi Street, Suzhou 215006, Jiangsu, P. R. China; 2Department of Clinical, Luohe Medical College, No. 148, Daxue Road, Luohe 462002, Henan, P. R. China; 3Department of Respiratory Medicine, The First Affiliated Hospital of Soochow University, No. 188, Shizi Street, Suzhou 215006, Jiangsu, P. R. China; 4Department of Interventional Radiology, The First Affiliated Hospital of Soochow University, No. 188, Shizi Street, Suzhou 215006, Jiangsu, P. R. China. *Equal contributors.

Received October 27, 2015; Accepted March 5, 2016; Epub March 15, 2016; Published March 30, 2016

Abstract: EGFL7 and E-Cadherin are abnormal expression in many malignant tumors, and involved in occurring and progressing of malignant tumors. The aim of this study is to investigate the expression of EGFL7 and E-Cadherin in human adenocarcinoma of esophagogastric junction (AEG) and explore their clinical and pathological significance. The expression of EGFL7 and E-Cadherin protein were detected in 146 cases of human AEG and 21 cases of tumor-adjacent tissues by immunohistochemical method. Our results demonstrate that the positive rate of EGFL7 was 63.7% in human AEG which was higher than that in tumor-adjacent tissues (19.0%), <0.001. High levels of EGFL7 protein were significantly correlated with tumor TNM classification and lymphatic metastasis and distant metastasis (P=0.002, P=0.021 and P=0.029, respectively). However, EGFL7 protein expression was not associated with gender, histopathological types and Siewert classification (P=0.925, P=0.938, P=0.369, respectively). The positive expression level of E-Cadherin was 41.8% in AEG, which was lower than that in tumor-adjacent tissues (85.7%), P<0.001. Low levels of E-Cadherin protein were significantly related with tumor histopathological types, TNM classification, Lymphatic metastasis and distant metastasis (P=0.008, P=0.014, P=0.019 and P=0.023, respectively). However, E-Cadherin protein expression was not associated with gender and Siewert classification (P=0.867, P=0.776, respectively). EGFL7 protein was negatively correlated with E-Cadherin protein (r=-0.429, P<0.001). Patients with higher EGLF7 or lower E-Cadherin expression had shorter overall survival time, while patients with lower EGFL7 or higher E-Cadherin expression had better survival time. In conclusion, expression of EGLF7 and E-Cadherin are markedly related with tumor TNM classification and lymphatic metastasis and distant metastasis of AEG. E-Cadherin is markedly related with tumor histopathological types of AEG. EGLF7 is negatively related with the expression of E-Cadherin. To detect EGLF7 and E-Cadherin may be helpful to evaluate prognosis and infiltrative capability of AEG.

Keywords: Adenocarcinoma of esophagogastric junction, immunohistochemistry, EGLF7, E-Cadherin, protein, survival

Introduction

Adenocarcinoma of the esophagogastric junction (AEG) is one of the most common malignant tumors of digestive system. The study indicated that compared with the declining of distal gastric adenocarcinoma, the incidence of AEG is rising rapidly in the world [1, 2]. The most effective treatment of AEG is radical resection. However, tumors are usually detected at the advanced stage due to atypical early symptoms. Therefore, some patients miss the golden chance of surgery, or the effect of the operation is not satisfactory. Obviously, the overall survival rate is not satisfactory [3]. It is well received that early diagnosis and early treatment are important for improving the prognosis of the patients with tumor [4]. Therefore, it is very important for the diagnosis and treatment of AEG to find some non-invasive tumor markers, which can effectively monitor tumor development. Thus, AEG can be early diagnosed and
EGFL7 and E-Cadherin in human adenocarcinoma

Table 1. Expressions of EGL7 and E-Cadherin in human adenocarcinoma of esophagogastric junction and tumor-adjacent tissues

<table>
<thead>
<tr>
<th>Tissue type</th>
<th>EGL7</th>
<th>E-Cadherin</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Negative (-)</td>
<td>Positive (+)</td>
</tr>
<tr>
<td>AEG tissue</td>
<td>53 (36.3)</td>
<td>93 (63.7)</td>
</tr>
<tr>
<td>tumor-adjacent tissue</td>
<td>17 (81.0)</td>
<td>4 (19.0)</td>
</tr>
<tr>
<td>$\chi^2$</td>
<td>15.034</td>
<td>14.216</td>
</tr>
<tr>
<td>$P$ value</td>
<td>&lt;0.001</td>
<td>&lt;0.001</td>
</tr>
</tbody>
</table>

Treated, leading to improving the operation effect and increasing the survival rate of patients.

The EGFL7 gene, also known as vascular endothelial-statin (VE-statin), which is overexpressed in many kinds of malignant tumors (such as liver cancer, prostate cancer, glioma and colon cancer), and it is closely related to the invasion and metastasis of malignant tumor [5-9]. Recent studies show that EGFL7 can regulate the adhesion of endothelial cell, inhibit the migration of vascular smooth muscle cells, thus delaying the maturation of blood vessels [10, 11]. Because of the EGFL7’s highly up-regulation, the degree of neonatal blood vessel maturation is comparatively low, the permeability of the tube wall is high for the lack of smooth muscle cells in the wound, so the cancer cells can easily pass through the wall of blood vessels, causing tumor invasion and metastasis [10, 11].

Pinte S found that EGFL7 could promote tumor metastasis by down regulating the expression of cell adhesion molecules on the surface of endothelial cells, which caused the tumor cells to escape the immune system [12]. Epithelial cadherin (E-cadherin) is a calcium dependent intercellular adhesion molecule that can mediate cell connection, maintain normal epithelial cell morphology and tissue structural integrity [13, 14]. Down-regulation or loss of E-cadherin reduced cell-cell adhesion, which enhanced the tumor cells’ potential for metastatic dissemination [15, 16].

AEG was divided into three types (type I, type II and type III) according to the anatomical features and the location of the tumor center, and the incidence rate of type I was the lowest among them [17, 18]. Type II/III was different from type I in etiology, origin, tumor biology, etc. These make type II/III AEG considered as an independent cancer compared with type I [18, 19].

In this study, we used immunohistochemical method to assay the expression of the EGFL7 and E-cadherin in 146 cases of AEG (Type II/III), which was aimed at exploring their clinical and pathological significance. They may be helpful to increase the detection rate of AEG and develop a practical diagnostic and monitoring prognosis tool for it.

Materials and methods

Patients

The study protocol was approved by the ethics committee of the First Affiliated Hospital of Soochow University, and all tissue samples were collected from patients with appropriate informed consent. 146 patients underwent surgery between March 2010 and March 2015. 21 cases of tumor-adjacent tissues were taken from the control group. Each patient with detailed clinical data and operation record. Among the 146 AEG samples, 104 were from male patients, and the rest 42 were from female patients of average age 60.3 (range from 38 to 85) years old. 67 patients have lymphatic metastasis (45.9%) and 24 patients had distant metastasis (16.4%), Among the 24 distant metastasis samples, 17 patients have abdominal metastasis and 9 patients have Liver metastasis. Sections were divided into well-modestly (97 cases) and poorly (49 cases) according to histopathological types. Sections were divided into T1/T2 (58 cases) and T3/T4 (90 cases) according to the TNM classification system proposed by American Joint Committee on Cancer (AJCC) in 2010 by two expert pathologists [20]. 65 patients were divided into type II and 81 patients were divided into type III according to Siewert classification [17]. AEG patients in the experimental group were shown in Tables 1 and 2. All sections were confirmed as human AEG by pathologists. Endoscopy or CT scan was performed once at 6-month intervals after surgery. They were followed up for 3 to 60 months via telephone. None of these patients received pre-operative chemotherapy or radiotherapy.
EGFL7 and E-Cadherin in human adenocarcinoma

Immunohistochemical (IHC) analysis

Immunohistochemical analysis was performed similarly as previously described [21]. The tumor tissues and tumor-adjacent tissues from AEG patients were fixed in 4% paraformaldehyde and were embedded in paraffin, and then were sectioned for IHC analysis. Specifically, each section needed to be deparaffinized, dehydrated and subjected to antigen retrieval. The slides filled with 0.01 mmol/L citrate buffer (pH 6.0) and were placed in a microwave oven for 15 mins. Then 3% hydrogen peroxide solution was used to block endogenous peroxidase activity for 10 mins at room temperature. After being washed with PBS, 3 times × 5 mins, slides were incubated for 1 h at room temperature with primary antibodies mouse anti-human-EFGL7 (1:100; Maixin Biotechnology Co. Ltd; Fuzhou, China) and mouse anti-human-E-Cadherin (1:100; Wuhan Boster Biological Technology, Ltd; Wuhan, China). Sections were washed in PBS 3 times × 5 mins, followed by further incubation with anti-mouse secondary antibody (Wuhan Boster Biological Technology, Ltd; Wuhan, China) for 15 mins at room temperature. 100 μL DAB solution (Wuhan Boster Biological Technology, Ltd; Wuhan, China) was dropped to each section (protect from light), then observed under the microscope. The slides were stained with hematoxylin. Each section was dehydrated with the alcohol, and processed transparently with xylene. PBS instead of primary antibodies was as negative controls.

Evaluating AEG-1 and Cyclin D1 staining

The sections were evaluated by the sum of two parts: (1) Percentage of positive cells: 0 (0-10% positive cells), 1 (10-40% positive cells), 2 (2=40-70% positive cells) and 3 (≥70% positive cells). (2) staining intensity (0=negative, 1=light yellow, 2=yellow brown, 3=brown). In the study, the EGFL7 and E-Cadherin expression is defined as positive (+, high expression) when score is more than or equal to 2, and negative (-, low expression) when the score is less than 2 [21].

Statistical analysis

Data are presented as mean ± standard deviation (S.D). Statistical analyses were performed with SASS v.9.2 and GraphPad Prism version 5.0 (GraphPad Software, San Diego, CA, USA). We compared the differences of enumeration data among different groups using χ² test (Tables 1 and 2). The relationship between EGFL7 and E-Cadherin expression was evalua-
Results

Relationship of EGFL7 and E-Cadherin expression and clinicopathological parameters

As is shown in Figure 1, EGFL7 expressions were indicated by yellow or brown in cytoplasm, and positive (Figure 1A), and negative (Figure 1B). E-Cadherin expressions were indicated by yellow or brown in cytomembrane, and positive (Figure 1C), and negative (Figure 1D).

As was shown in Tables 1 and 2, the positive rate of EGFL7 was 63.7% in AEG tissues which was higher than that in tumor-adjacent tissues (19.0%), <0.001. High levels of EGFL7 protein were significantly related to tumor TNM classification and lymphatic metastasis and distant metastasis (P=0.002, P=0.021 and P=0.029, respectively). However, EGFL7 protein expression was not associated with gender, histopathological types and Siewert classification (P= 0.925, P=0.938, P=0.369, respectively). The positive rate of E-Cadherin was 41.8% in AEG tissues, which was lower than that in tumor-adjacent tissues (85.7%), P<0.001. Low levels of E-Cadherin protein were significantly related to tumor histopathological types, TNM classification, Lymphatic metastasis and distant metastasis (P=0.008, P=0.014, P=0.019 and P=0.023, respectively). However, E-Cadherin protein expression was not associated with gender and Siewert classification (P=0.867, P=0.776, respectively).

Correlations between expressions of EGFL7 and E-Cadherin and survival

The correlations were shown in Figure 2. Kaplan-Meier survival curves of AEG patients based on EGFL7 or E-Cadherin expression. Patients with high EGFL7 expression showed significantly worse survival compared to those patients with low expression (P<0.001, log-rank test) (Figure 2A). Patients with low E-Cadherin expression showed significantly worse survival compared to those patients with high E-Cadherin expression (P<0.001, log-rank test) (B). Cox multivariate analysis showed that TNM classification, lymphatic metastasis and distant metastasis as well as EGFL7 expression levels were negatively correlated with AEG survival, and positively correlated with E-Cadherin expression levels, suggesting that high levels of EGFL7 and low levels of E-Cadherin are relative risk factors for prognosis (Table 3).

Correlations between EGFL7 and E-Cadherin expression in AEG tissue and clinicopathological parameters

There is a negative correlation between EGFL7 and E-Cadherin expressions in AEG tissue (r=-0.429, P<0.001), as is shown in Table 4.
Discussion

In this study, the positive rate of EGFL7 in AEG was significantly higher than that of the tumor-adjacent tissue, suggesting that EGFL7 may participate in AEG tumorigenesis. However, EGFL7 expression levels were not significantly correlated with hispathological types in AEG patients, maybe due to the relatively small sample size. In addition, the positive rate of EGFL7 had no relationship with gender and Siewert classification. The positive rate of EGFL7 was closely related to the TNM classification, lymphatic metastasis and distant metastasis, suggesting that EGFL7 played a role in the progression of AEG. The research
found that the patients with high EGFL7 expression had short survival time. By contrast, the patients with lower expression had a favorable effect and comparatively long survival time [6, 9, 22, 23].

Therefore, EGFL7 is expected to be an independent tumor prognostic factor. Our follow-up results also showed that the patients with high EGFL7 expression had worse survival time compared with those with low EGFL7 expression. Cox multivariate analysis also suggested that high EGFL7 expression was strongly associated with a higher hazard ratio and unfavorable clinical outcomes. With more studies about mechanism of EGFL7 and tumor proliferation, apoptosis, and malignant progress, EGFL7 as the target drugs of gene therapy also gets more and more attention. Making the EGFL7 gene inactive by using RNA interference can reduce the proliferation and the invasion ability of tumor cells [24-26]. In combination with the scholars’ researches, EGFL7 protein may be helpful for auxiliary diagnosis of bladder cancer and the judgment of patient prognosis, which may become the new target for tumor gene therapy.

This study found that the positive rate of E-cadherin in AEG tissue cells were significantly lower than that in the tumor-adjacent tissue. E-cadherin expression in poorly was much lower than well-moderately in histopathological stage, and the higher pathologic the stage was, the lower the positive rate was. These suggested that E-cadherin may be a tumor inhibition factor participating in AEG.

Low expression of E-Cadherin is closely related to the TNM classification, lymphatic metastasis and distant metastasis, which indicated that the loss of E-cadherin protein function could lead to the invasion and metastasis of tumor. Studies showed that patients with low E-Cadherin expression had poor prognosis [27, 28]. Our study also showed that patients with low E-cadherin expression showed significantly worse survival compared with those with high E-cadherin expression. Cox multivariate analysis also suggested that low E-cadherin expression was strongly associated with a higher hazard ratio and unfavorable clinical outcomes. It may be considered for auxiliary diagnosis of AEG, and judging the prognosis of patients.

Wang YL found that EGFL7 had certain adjustment effect for E-cadherin protein. They found that E-cadherin protein expression increased significantly when the expression of EGFL7 protein was inhibited by using RNA interference [29]. It suggested that EGFL had a negative regulatory effect on E-cadherin protein and it might be related to Epithelial-Mesenchymal Transition (EMT). EMT could promote tumor cell infiltration and tumor metastasis [30, 31]. Luo BH researched that EGFL7 promoted tumor invasion by activating EMT through an EGFR-AKT-Snail signaling pathway in gastric cancer [25]. The research showed that snail, the transcription factor, could down regulate the expression of E-cadherin, which could induce the occurrence of EMT [32].

Our study also found that the expression of EGFL7 was up-regulated, while the expression of E-cadherin protein in AEG was down-regulated, and they were negatively correlated. The specific mechanism that EGFL7 regulate E-cadherin is still unknown. Combined with the literature, we speculate that it may be related to EMT, but its specific mechanism needs to be further studied.

Conclusion

In conclusion, compared with tumor-adjacent tissues, positive expression rates of Egfl7 in AEG tissues are significantly higher, while rates of E-cadherin in AEG tissues are significantly lower. EGFL7 and E-cadherin expression were closely related to tumor progression and metastasis in AEG. They are a valuable index to determine the biological behavior of AEG and combined detection of them can be used as an important index to evaluate the prognosis of AEG.

Acknowledgements

This study was supported by National Science Foundation of China (No. 81302148), (No. 81-501563) and (No. 81302146), Natural Science Research Foundation of Colleges and Universities in Jiangsu Province (13KJB320019) and (13KJB320018), the Science and Technology Bureau and Sanitary Bureau of Suzhou (KJXW2011008) and (KJXW 2013003).

Disclosure of conflict of interest

None.
EGFL7 and E-Cadherin in human adenocarcinoma

Address correspondence to: Dr. Jin Zhou, Department of General Surgery, The First Affiliated Hospital of Soochow University, No. 188, Shizi Street, Suzhou 215006, Jiangsu, P. R. China. Tel: +86-512-67780107; Fax: +86-512-67780107; E-mail: z11-63548@sina.com

References


[22] Zhou L, Li J, Zhao YP, Guo JC, Cui QC, Zhou WX, Zhang TP, Wu WM, You L and Shu H. Prognostic significance of epidermal growth factor-like do-